Methods and compositions for attenuating anti-viral transfer vector immune responses

Abstract

Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.

1 . A method comprising:
 establishing an anti-viral transfer vector attenuated response in a subject by concomitant administration of an antigen-presenting cell targeted immunosuppressant and viral transfer vector to the subject,   wherein the subject does not have pre-existing immunity against the viral transfer vector.   
     
     
         2 - 6 . (canceled) 
     
     
         7 . A method comprising:
 attenuating an anti-viral transfer vector response, wherein the anti-viral transfer vector response is a T cell response, by first administering to a subject a viral transfer vector without an antigen-presenting cell targeted immunosuppressant, and   subsequently concomitantly administering the viral transfer vector and an antigen-presenting cell targeted immunosuppressant to the subject.   
     
     
         8 . The method of  claim 7 , further comprising administering to the subject one or more repeat doses of the viral transfer vector subsequent to the concomitant administration of the viral transfer vector and the antigen-presenting cell targeted immunosuppressant to the subject. 
     
     
         9 - 16 . (canceled) 
     
     
         17 . A method comprising:
 repeatedly, concomitantly administering to a subject an antigen-presenting cell targeted immunosuppressant and viral transfer vector, and   selecting one or more doses of the viral transfer vector to be less than the dose of the viral transfer vector that would be selected for the subject if the subject were expected to develop anti-viral transfer vector immune responses due to the repeated administration of the viral transfer vector.   
     
     
         18 - 25 . (canceled) 
     
     
         26 . A method comprising:
 inducing an entity to purchase or obtain an antigen-presenting cell targeted immunosuppressant alone or in combination with a viral transfer vector by communicating to the entity that efficacious repeated viral transfer vector dosing is possible by concomitant administration of the antigen-presenting cell targeted immunosuppressant and viral transfer vector to a subject.   
     
     
         27 - 38 . (canceled) 
     
     
         39 . The method of  claim 1 , wherein the concomitant administration is simultaneous administration. 
     
     
         40 . The method of  claim 1 , wherein the subject is one to which the viral transfer vector has not been previously administered. 
     
     
         41 . The method of  claim 1 , wherein the viral transfer vector is a retroviral transfer vector, an adenoviral transfer vector, a lentiviral transfer vector or an adeno-associated viral transfer vector. 
     
     
         42 - 46 . (canceled) 
     
     
         47 . The method of  claim 1 , wherein the transgene of the viral transfer vector comprises a gene therapy transgene, a gene editing transgene, an exon skipping transgene or a gene expression modulating transgene. 
     
     
         48 - 71 . (canceled) 
     
     
         72 . The method of  claim 1 , wherein the antigen-presenting cell targeted immunosuppressant comprises an erythrocyte-binding therapeutic. 
     
     
         73 - 75 . (canceled) 
     
     
         76 . The method of  claim 1 , wherein the antigen-presenting cell targeted immunosuppressant comprises a negatively-charged particle. 
     
     
         77 - 80 . (canceled) 
     
     
         81 . The method of  claim 1 , wherein the antigen-presenting cell targeted immunosuppressant comprises an apoptotic-body mimic and one or more viral transfer vector antigens. 
     
     
         82 - 85 . (canceled) 
     
     
         86 . The method of  claim 1 , wherein the antigen-presenting cell targeted immunosuppressant comprises synthetic nanocarriers comprising an immunosuppressant. 
     
     
         87 - 114 . (canceled) 
     
     
         115 . The method of  claim 1 , wherein the immunosuppressant is an inhibitor of the NF-kB pathway. 
     
     
         116 . The method of  claim 1 , wherein the immunosuppressant is rapamycin. 
     
     
         117 . (canceled)